Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Inhibikase Therapeutics, Inc. Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.	United States of America	IKT
Inhibrx Biosciences, Inc. Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.	United States of America	INBX
InMed Pharmaceuticals Inc. Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.	United States of America	INM
Inmune Bio, Inc. Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.	United States of America	INMB
Innate Pharma SA Developing first-in-class antibody immunotherapies for cancer via the innate immune system.	United States of America	IPHA
INOVIO PHARMACEUTICALS, INC. Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.	United States of America	INO
Insight Molecular Diagnostics Inc. Develops molecular diagnostic tests for oncology and transplant monitoring for clinicians & researchers.	United States of America	IMDX
INSMED Inc Develops and commercializes innovative therapies for serious and rare diseases.	United States of America	INSM
Instil Bio, Inc. Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.	United States of America	TIL
Intellia Therapeutics, Inc. Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.	United States of America	NTLA